UC San Diego Innovation Calendar
MET Bldg, Learning Center 141 and 143
Chimeric antigen (CAR)-engineered T cells have shown tremendous promise in treating cancers such as B cell malignancies. It has been reported that up to 90% complete remission is seen with anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia. Thus, CAR-T is, and will continue to be, an exciting and active area of research.
This presentation provides an up to date look at CAR-T cell research and development to inform intellectual property strategies. We will review the first, second, and third generation CAR-T cell therapies and the most dominant players, as well as the patenting strategies each has taken in this space.